Medicare Part D

Analysis Finds That a Relatively Small Number of Drugs Account for the Majority of Medicare Prescription Drug Spending

  • by

A new KFF analysis finds that a relatively small share of drugs, mainly those without generic or biosimilar competitors, accounted for a disproportionate share of prescription drug spending in Medicare in 2019. This finding suggests that recent proposals that focus on prices for a limited… Read More »Analysis Finds That a Relatively Small Number of Drugs Account for the Majority of Medicare Prescription Drug Spending

Relatively Few Drugs Account for a Large Share of Medicare Prescription Drug Spending

  • by

As policymakers focus attention on proposals to lower prescription drug costs by allowing price negotiation or international reference pricing for a limited number of drugs, this analysis measures the share of total Medicare Part D and Part B prescription drug spending accounted for by top-selling… Read More »Relatively Few Drugs Account for a Large Share of Medicare Prescription Drug Spending

A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration

  • by

This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug… Read More »A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration

Options to Make Medicare More Affordable For Beneficiaries Amid the COVID-19 Pandemic and Beyond

  • by

Medicare provides significant health and financial protections to more than 60 million Americans, but there are gaps in coverage and high cost-sharing requirements that can make health care difficult to afford. This report analyzes several policy options that could help make health care more affordable… Read More »Options to Make Medicare More Affordable For Beneficiaries Amid the COVID-19 Pandemic and Beyond